OmniAb, Inc.

OmniAb, Inc.

OABINYSE / NASDAQHealthcareSmall cap

$4.66-$0.37 (-7.4%)

Last close · Data as of Nov 20, 2026

Market cap
$385.6M
P/E
-6.0x
EV / EBITDA
-8.1x
Revenue
$18.7M
Net margin
-347.0%
ROCE
-24.2%

+179.0% over the last year

OmniAb, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-6.0%
3M
+8.4%
6M
+80.6%
1Y
+179.0%
5Y
Hidden
  • This period includes a one-day price step on 2 Nov 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.37 (-7.4%) from $5.03 to $4.66 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in OABI, bought on each weekday since 2021.

News & filings

What OmniAb filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 64.8 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 58.6% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.

Read moreShow less

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Sector
Healthcare
Shares outstanding
144.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$385.6M
P/E
-6.0x
P/B
1.4x
EV / EBITDA
-8.1x
EV / Sales
20.4x
P/S
20.7x
52-week high
$5.30
52-week low
$1.36

Profitability

Operating margin
-369.5%
Net margin
-347.0%
EBITDA margin
-252.9%
ROE
-24.3%
ROCE
-24.2%
ROIC
-20.8%
ROA
-21.5%
Asset turnover
0.06

Growth

Revenue
$18.7M
Revenue growth, 1Y
-29.3%
Revenue CAGR, 3Y
-31.9%
Net profit growth, 1Y
4.4%
Free cash flow
-$37.0M

Solvency

Current ratio
4.02
Debt / Equity
0.08
Debt / Assets
0.07
CFO / Net profit
0.56
Cash / Market cap
6.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$18.7M
Cost of revenue$300.0k
Gross profit$18.4M
Operating expenses$87.3M
Research and development$47.8M
Selling, general and administrative$29.2M
Operating income-$69.0M
Interest and other$2.7M
Pretax income-$66.3M
Tax and other-$1.5M
Net income-$64.8M

Revenue and net profit

Revenue fell 29.3% in FY2025; net profit is the dashed line.

OmniAb, Inc. revenue and net profit by fiscal year
OmniAb, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$59.1M-$22.3M
FY2023$34.2M-$50.6M
FY2024$26.4M-$62.0M
FY2025$18.7M-$64.8M

Cash flows

FY2025: -$36.5M from operations, -$37.0M free after investment (dashed).

OmniAb, Inc. operating and free cash flow by fiscal year
OmniAb, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$3.6M-$20.8M
FY2023$2.3M$703.0k
FY2024-$39.7M-$41.5M
FY2025-$36.5M-$37.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$18.7M-29.3%1Y
EBITDA
-$47.2M
Net profit
-$64.8M
Cash from operations
-$36.5M
Free cash flow
-$37.0M
Revenue CAGR, 3Y
-31.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$18.7M-$47.2M-$64.8M-$37.0M-24.3%-29.3%+4.4%

Monthly returns

Month-by-month returns of OABI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$300.9M
Liabilities$33.9M
Equity$267.0M
Paid-in capital$433.2M
Retained earnings-$166.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; OABI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. OmniAb, Inc. (this company)20.4x

Not shown (no positive earnings and no EV / Sales): Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
OmniAb, Inc.OABIthis company$385.6M-6.0x1.4x-24.3%-8.1x
Community Health Systems, Inc.CYH$393.2M0.8x-0.3x-36.5%5.5x
TruBridge, Inc.TBRG$390.7M89.7x2.2x2.4%12.5x
Compass Therapeutics, Inc.CMPX$383.6M-5.8x1.9x-33.8%-5.1x
Benitec Biopharma Inc.BNTC$379.6M-10.0x3.9x-39.0%-6.8x
Viemed Healthcare, Inc.VMD$377.2M25.3x2.7x10.6%7.4x
CapsoVision, Inc.CV$376.7M-14.9x28.4x-190.9%-14.7x
Vanda Pharmaceuticals Inc.VNDA$375.8M—1.1x-67.4%—
Lexeo Therapeutics, Inc.LXEO$375.3M-3.8x1.5x-40.5%-3.3x
Peer median—-3.8x2.1x-37.7%-3.3x

Year-to-date ROI

OABI since 1 January, against earlier years.

Historical volatility

OABI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

OmniAb, Inc. operating margin by fiscal year
OmniAb, Inc. operating margin by fiscal year
DateOperating margin
FY2022-45.1%
FY2023-203.2%
FY2024-282.3%
FY2025-369.4%
LineFY2025
Cost of revenueCost Of Revenue$300.0k
Gross profitGross Profit$18.4M
Operating expensesOperating Expense$87.3M
Research and developmentResearch And Development$47.8M
Other operating expensesOther Operating Expenses-$2.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$12.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$12.9M
Amortization$12.9M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$12.9M
Total expensesTotal Expenses$87.6M
Pretax incomePretax Income-$66.3M

Learn while you research

Academy chapters picked for OmniAb, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →